Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort is at an inflection point because its core Life Sciences Services business has delivered about six straight quarters of 15% to 20% year-over-year growth, now represents 57% of revenue, and is benefiting from rising commercial CGT adoption as 22 approved therapies and 94 Phase 3 trials expand the recurring revenue base. In 2Q:26, the company generated $49 million of revenue, posted positive adjusted EBITDA of $0.4 million for the first time since 1Q:23, and produced about $5 million of positive operating cash flow in 1H 2026, signaling improving scale and operating leverage. Its outlook is further strengthened by higher-value catalysts such as BioStorage/BioServices growth, the IntegriCell rollout, and upcoming Paris and Santa Ana facility launches in Q4 2026, while MVE and new freezer products add resilience and optionality.

Bears say

CryoPort is facing a less attractive fundamental setup as growth in its core cell and gene therapy end market depends on a slower-than-expected pace of approvals, which management and the bear case note could weaken both revenue and profitability. Total revenue rose only 8% organically to $49M, with Life Sciences Services up 15% to $28M but Life Sciences Products flat at $21M and missing consensus, highlighting uneven demand and softness in the higher-risk Products business. Ongoing macro pressure on MVE, competition in cold-chain logistics, and the possibility of fewer commercial product flows all threaten margins and could keep valuation under pressure.

CryoPort (CYRX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, CryoPort (CYRX) has a Strong Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.